PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
LA JOLLA, Calif. , Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that  Nature Communications  has published an article entitled, "Discovery
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
LA JOLLA, Calif. , Aug. 29, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dose Studies with RGLS4326 Appointment of Cris
View HTML
Toggle Summary Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
LA JOLLA, Calif. , July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective
View HTML
Toggle Summary Regulus Therapeutics Announces RGLS4326 Program Update
Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326 Single Ascending Dose Studies With RGLS4326 May Be Pursued LA JOLLA, Calif. , July 23, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the
View HTML
Toggle Summary Regulus Announces New Additions to Board of Directors
LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ --   Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D.
View HTML
Toggle Summary Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Engagement with FDA on RGLS4326 Clinical Program Ongoing LA JOLLA, Calif. , May 9, 2019 /PRNewswire/ -- Regulus Therapeutics
View HTML
Toggle Summary Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche of its previously announced private placement
View HTML
Toggle Summary Regulus Therapeutics Announces Restructuring of Term Loan
Term Loan Amended to Provide Up to Two Years of Interest Only Payments and Extension of Maturity Date to May 2022 LA JOLLA, Calif. , May 6, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines
View HTML